SG10201913641XA - Viral Prophylaxis Treatment Methods and Pre-Exposure Prophylaxis Kits - Google Patents

Viral Prophylaxis Treatment Methods and Pre-Exposure Prophylaxis Kits

Info

Publication number
SG10201913641XA
SG10201913641XA SG10201913641XA SG10201913641XA SG10201913641XA SG 10201913641X A SG10201913641X A SG 10201913641XA SG 10201913641X A SG10201913641X A SG 10201913641XA SG 10201913641X A SG10201913641X A SG 10201913641XA SG 10201913641X A SG10201913641X A SG 10201913641XA
Authority
SG
Singapore
Prior art keywords
prophylaxis
kits
treatment methods
viral
exposure
Prior art date
Application number
SG10201913641XA
Other languages
English (en)
Inventor
Emidio A Checcone
Christina Ramirez
Original Assignee
Elian Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elian Llc filed Critical Elian Llc
Publication of SG10201913641XA publication Critical patent/SG10201913641XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
SG10201913641XA 2014-07-07 2015-07-07 Viral Prophylaxis Treatment Methods and Pre-Exposure Prophylaxis Kits SG10201913641XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462021589P 2014-07-07 2014-07-07

Publications (1)

Publication Number Publication Date
SG10201913641XA true SG10201913641XA (en) 2020-03-30

Family

ID=55016233

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201700061PA SG11201700061PA (en) 2014-07-07 2015-07-07 Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
SG10201913641XA SG10201913641XA (en) 2014-07-07 2015-07-07 Viral Prophylaxis Treatment Methods and Pre-Exposure Prophylaxis Kits

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201700061PA SG11201700061PA (en) 2014-07-07 2015-07-07 Viral prophylaxis treatment methods and pre-exposure prophylaxis kits

Country Status (14)

Country Link
US (1) US10052329B2 (pt)
EP (2) EP3166680B1 (pt)
JP (3) JP2017527610A (pt)
KR (1) KR20170063512A (pt)
CN (2) CN114469958A (pt)
AU (3) AU2015287994B2 (pt)
BR (1) BR112017000285A2 (pt)
CA (1) CA2954526C (pt)
ES (1) ES2964529T3 (pt)
IL (2) IL249938B (pt)
MX (1) MX2017000059A (pt)
PL (1) PL3166680T3 (pt)
SG (2) SG11201700061PA (pt)
WO (1) WO2016007538A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016007538A1 (en) 2014-07-07 2016-01-14 Prophylaxis, Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
US11071745B2 (en) * 2014-07-07 2021-07-27 Elian Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
JP7019727B2 (ja) * 2017-02-08 2022-02-15 バイオトロン リミティッド インフルエンザの治療方法
UA126076C2 (uk) * 2017-06-28 2022-08-10 Айкуріс Ґмбг Унд Ко. Кґ Пристрій для інтравагінального введення прителівіру
US20210379089A1 (en) * 2018-10-23 2021-12-09 Eastern Virginia Medical School Pharmaceutical compositions and methods of making on demand solid dosage formulations
WO2020092990A1 (en) * 2018-11-02 2020-05-07 Eastern Virginia Medical School Pharmaceutical compositions and methods of making a patch formulation for transdermal delivery
CN113727715A (zh) 2019-02-25 2021-11-30 艾利安有限责任公司 用伐昔洛韦和泛昔洛韦的组合治疗单纯疱疹
CN114929212A (zh) * 2019-10-29 2022-08-19 传明科技有限责任公司 用于增强功效的合成的赖氨酸类似物、衍生物、模拟物或前药与药剂的协同组合
US20210322469A1 (en) * 2020-04-20 2021-10-21 Regents Of The University Of Minnesota Zinc and copper for the prophylaxis and treatment of covid-19

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795721A (en) 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
NZ507609A (en) * 1998-04-21 2003-09-26 Infectio Recherche Inc Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
US20020091097A1 (en) * 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
CN101405010B (zh) * 2006-03-22 2013-03-06 星药股份有限公司 避孕组合物
WO2009142827A2 (en) * 2008-03-28 2009-11-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and methods for the treatment of viral infection
US8853223B2 (en) * 2010-09-17 2014-10-07 G2L Touch, Inc. Therapeutic composition to treat lesions caused by herpes simplex virus
BR112012031497A2 (pt) * 2010-06-11 2016-11-01 Ayesha Kharsany formulações antivirais tópicas para a prevenção de transmissão de hsv-2
WO2012158779A1 (en) * 2011-05-17 2012-11-22 Reprotect, Inc. Reusable intravaginal delivery device, system, and method
KR20140074281A (ko) * 2011-07-20 2014-06-17 패트릭 에프. 카이저 약물 전달용 질내 장치
EA034351B1 (ru) * 2012-05-16 2020-01-30 Иммьюн Дизайн Корп. Трехкомпонентная вакцина против впг-2 и способы ее применения
WO2016007538A1 (en) 2014-07-07 2016-01-14 Prophylaxis, Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits

Also Published As

Publication number Publication date
JP2017527610A (ja) 2017-09-21
SG11201700061PA (en) 2017-02-27
US20160000797A1 (en) 2016-01-07
AU2015287994B2 (en) 2020-03-12
IL249938A0 (en) 2017-03-30
ES2964529T3 (es) 2024-04-08
AU2015287994A1 (en) 2017-02-02
CN106794336A (zh) 2017-05-31
EP3166680A4 (en) 2018-01-17
AU2020203896A1 (en) 2020-07-02
IL273932A (en) 2020-05-31
IL273932B1 (en) 2023-03-01
JP2021138723A (ja) 2021-09-16
US10052329B2 (en) 2018-08-21
AU2020203896B2 (en) 2022-08-25
AU2022275517A1 (en) 2023-01-05
IL249938B (en) 2020-04-30
PL3166680T3 (pl) 2024-03-25
BR112017000285A2 (pt) 2017-10-31
IL273932B2 (en) 2023-07-01
MX2017000059A (es) 2017-11-08
EP4342545A2 (en) 2024-03-27
JP2023179575A (ja) 2023-12-19
EP3166680C0 (en) 2023-11-15
KR20170063512A (ko) 2017-06-08
CN114469958A (zh) 2022-05-13
CA2954526A1 (en) 2016-01-14
CN106794336B (zh) 2022-01-11
WO2016007538A1 (en) 2016-01-14
CA2954526C (en) 2023-03-07
EP3166680B1 (en) 2023-11-15
EP4342545A3 (en) 2024-06-26
EP3166680A1 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
HK1258795A1 (zh) 絲狀病毒科病毒感染的治療方法
HK1243640A1 (zh) 用於治療潰瘍的方法和組合物
HK1252937A1 (zh) 用於治療抑鬱症的方法和試劑盒
GB201701673D0 (en) Methods of well treatment
IL249938A0 (en) Methods and kits for preventive treatment before exposure to viral infection
IL248803A0 (en) Means and methods for treating cmv
EP3229906C0 (en) SYSTEMS AND METHODS FOR OPTIMIZING TRANSCRANIAL ACOUSTIC TREATMENT
IL251759B (en) Preparations and methods for treating insomnia
EP3133919A4 (en) Agents and methods for treatment of pathogens
IL251885B (en) Noscapinoid Producing Bacteria and Methods for Their Preparation and Use
EP3174475C0 (en) CATHETER DEVICES AND KITS
GB201416832D0 (en) Methods of treatment
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
IL246643A0 (en) Preparations and kits for the treatment of immunodeficiency virus/acquired immunodeficiency syndrome
GB201402909D0 (en) Treating infection
GB201417372D0 (en) Methods and kits
HK1244782A1 (zh) 用於治療疾病和病癥的組合物和方法
GB201412010D0 (en) Treatment of hypertransaminasemia
EP3215180A4 (en) Methods and kits for treating cardiovascular diseases
GB201512139D0 (en) Methods of treatment
GB201421904D0 (en) Methods and kits
GB201509908D0 (en) Methods and kits
AU2014902732A0 (en) Treatment and prophylaxis
AU2014901470A0 (en) Agents and methods for treatment of pathogens